BLRX 241220 2.00P (BLRX241220P2000) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

BLRX241220P2000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 22 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

12 Health Care Stocks Moving In Thursday's Pre-Market Session
BenzingaNov 21 16:06 ET
BioLineRx Inks Licensing Deal, Share Purchase Agreement
Seeking AlphaNov 21 08:00 ET
BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial...
BenzingaNov 21 06:33 ET
Express News | BioLine RX Ltd - Transactions to Reduce Biolinerx's Operational Expenses and Debt
ReutersNov 21 06:30 ET
Express News | BioLine RX Ltd - Biolinerx to Receive $10 Mln Upfront, up to $87 Mln in Milestones
ReutersNov 21 06:30 ET
Earnings Preview: BioLine Rx to Report Financial Results Pre-market on November 25
Moomoo NewsNov 20 14:54 ET

Comments

Trytosaveabit

Nov 21 05:35

Hehehe! Here’s the rest!

$BioLine Rx (BLRX.US)$ BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda
Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous...

Trytosaveabit

Nov 21 05:32

Hmm! News

$BioLine Rx (BLRX.US)$ Reuters· 1 min ago
BioLine RX Ltd - Biolinerx to Receive $10 Mln Upfront, up to $87 Mln in Milestones

13112024

Nov 21 04:03

$BioLine Rx (BLRX.US)$ all leaving, too expensive sell more than $1

Jaguar8

Nov 5 08:02

NEWS

$BioLine Rx (BLRX.US)$
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
BioLineRx (NASDAQ: BLRX) announced positive initial results from a Phase 1 clinical trial evaluating motixafortide for stem cell mobilization in sickle cell disease (SCD) gene therapies. The study showed that motixafortide, both alone and combined with natalizumab, was safe...

Trytosaveabit

Oct 16 06:18

News

$BioLine Rx (BLRX.US)$ BioLineRx Announces USPTO Allowance Of New Composition Of Matter Patent Covering Composition Of Motixafortide